Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. No trace of phase: Corticomotor excitability is not tuned by phase of pericentral mu-rhythm

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Objective and subjective stress, personality, and allostatic load

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Altered orbitofrontal sulcogyral patterns in gambling disorder: a multicenter study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There is a large unmet need for treatments for patients with progressive multiple sclerosis (MS). Phase 2 studies with cerebrospinal fluid (CSF) biomarker outcomes may be well suited for the initial evaluation of efficacious treatments.

OBJECTIVE: To evaluate the effect of monthly oral methylprednisolone pulse treatment on intrathecal inflammation in progressive MS.

METHODS: In this open-label phase 2A study, 15 primary progressive and 15 secondary progressive MS patients received oral methylprednisolone pulse treatment for 60 weeks. Primary outcome was changes in CSF concentrations of osteopontin. Secondary outcomes were other CSF biomarkers of inflammation, axonal damage and demyelination; clinical scores; magnetic resonance imaging measures of disease activity, magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI); motor evoked potentials; and bone density scans.

RESULTS: We found no change in the CSF concentration of osteopontin, but we observed significant improvement in clinical scores, MTR, DTI and some secondary CSF outcome measures. Adverse events were well-known side effects to methylprednisolone.

CONCLUSION: Monthly methylprednisolone pulse treatment was safe, but had no effect on the primary outcome. However, improvements in secondary clinical and MRI outcome measures suggest that this treatment regimen may have a beneficial effect in progressive MS.

Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume22
Issue number7
Pages (from-to)926-934
Number of pages9
ISSN1352-4585
DOIs
Publication statusPublished - Jun 2016

ID: 45677587